• 1
    Lee W. Hepatitis B virus infection. N Engl J Med 1997; 337: 173345.
  • 2
    Lok AS & Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 1990; 10(1): 2934.
  • 3
    Davies GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984; 86: 2305.
  • 4
    Gupta S, Govindarajan S, Fong TL, Redeker AG. Spontaneous reactivation of chronic hepatitis B: patterns and natural history. J Clin Gastroenterol 1990; 12(5): 5628.
  • 5
    Levy P, Marcellin P, Martinot-Peignoux M, Degott C, Nataf J, Benhamou JP. Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Hepatology 1990; 12(3 Part 1): 5704.
  • 6
    Vickers C, Neuberger J, Buckels McMaster P, Elias E. Transplantation of liver in adults and children with fulminant liver failure. J Hepatol 1988; 7: 14350.
  • 7
    Chapman RW, Forman D, Peto R, Smallwood R. Liver transplantation for acute hepatic failure. Lancet 1990; 335: 325.
  • 8
    Lee WM. Medical progress: acute liver failure. N Engl J Med 1993; 329: 186272.
  • 9
    Iwatsuki S, Striber AC, Marsh JW, et al. Liver transplantation for fulminant hepatic failure. Transplant Proc 1989; 21: 24314.
  • 10
    Samuel D & Bismuth H. Liver transplantation in patients with fulminant liver failure. In: Maddrey WC, Schiff ER, Sorrell MF, eds. Transplantation of the Liver, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2001: 361–70.
  • 11
    Lai CL, Chien RN, Leung NWY, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 618.
  • 12
    Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341(17): 125663.
  • 13
    Ter Borg F, Smorenburg S, De Man RA, Rietbroek RC, Chamuleau RA, Jones EA. Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 1998; 43(10): 226770.
  • 14
    Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphoma. Ann Oncol 1998; 9(4): 3857.DOI: 10.1023/A:1008206519571
  • 15
    Yeo W, Steinberg JL, Tam JS, et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999; 59(3): 2639.DOI: 10.1002/(SICI)1096-9071(199911)59:3<263::AID-JMV1>3.3.CO;2-O
  • 16
    Villeneuve J-P, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 20710.
  • 17
    Yao FY & Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 3017.
  • 18
    Kapoor D, Guptan RC, Wakil SM, et al. Beneficical effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 30812.
  • 19
    Trey C & Davidson LS. The management of liver failure. In: Popper H, Schaffner F, eds. Progress in Liver Disease. New York: Grune and Stratton, 1970: 282–98.
  • 20
    Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbations in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology 1987; 7: 203.
  • 21
    O'Grady JG, Alexander GJ, Hayllor KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97(2): 43945.
  • 22
    Tassopoulos NC, Volepes R, Pastores G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Mutant Study Group. Hepatology 1999; 29(3): 88996.
  • 23
    Yeo W, Chan PK, Zang S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62(3): 299307.DOI: 10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0
  • 24
    Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46(29): 292530.
  • 25
    Lau GKK, Liang R, Wu PC, Lee CK, Lin WL, Au WY . Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol 1998; 28(3): 35968.
  • 26
    Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100(1): 1828.
  • 27
    Tsubota A, Arase Y, Saitoh S, et al. Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B infection: a preliminary study.Am J Gastroenterol 2001; 96(2): 55762.
    Direct Link:
  • 28
    Lo CM, Fan ST, Liu CL, et al. Applicability of live donor liver transplantation to high urgency patients. Transplantation 1999; 67(1): 737.
  • 29
    Huo TI, Wu JC, Sheng WY, et al. Prognostic factor analysis of fulminant and subfulminant hepatic failure in an area endemic for hepatitis B. J Gastroenterol Hepatol 1996; 11(6): 5605.
  • 30
    Ring-Larson Palazzo U. Renal failure in fulminant hepatic failure and terminal cirrhosis: a comparison between incidence, types, and prognosis. Gut 1981; 22: 585585.
  • 31
    Chang TT, Lai CL, Liaw YF, et al. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine [Abstract]. Hepatology 1999; 30(4): 420A420A.
  • 32
    Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30(4): 10827.
  • 33
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable with chronic hepatitis B in Korea. Hepatology 2000; 32(4): 8036.